Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus

Archives of Virology

Volumn 155, Issue 10, 2010, Pages 1587-1595

  Lazo, Laura ^a   Gil, Lázaro ^a   Lopez, Carlos ^a   Valdes, Iris ^a   Marcos, Ernesto ^a   Álvarez, Mayling ^b   Blanco, Aracelys ^a   Romero, Yaremis ^a   Falcon, Viviana ^a   Guzmán, María G ^b   Guillén, Gerardo ^a   Hermida, Lisset ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; LPDA PROTEIN, NEISSERIA MENINGITIDIS; OUTER MEMBRANE PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENGUE; DENGUE VIRUS; FEMALE; GENETICS; IMMUNOLOGY; MOUSE; SECRETION; SURVIVAL; TH1 CELL; VIRUS NUCLEOCAPSID; SECRETION (PROCESS);

ANIMALS; ANTIBODIES, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; NUCLEOCAPSID; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TH1 CELLS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

ANIMALIA; DENGUE VIRUS; DENGUE VIRUS TYPE 2; MUS; NEISSERIA MENINGITIDIS;

EID: 77957344542     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-010-0734-9     Document Type: Article

References (48)

1. Edelman R (2007) Dengue vaccines approach the finish line. Clin Infect Dis 45(Suppl 1): S56-S60.
2. Grgacic EV, Anderson DA (2006) Virus-like particles, passport to immune recognition. Methods 40: 60-65.
3. Sugrue RJ, Fu J, Howe J, Chan YC (1997) Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J Gen Virol 78(Pt 8): 1861-1866.
4. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G (2005) Influenza virus-like particles comprised of the HA, NA and M1 proteins of H9N2 influenza virus induce protective immune response in balb/c mice. Vaccine 23: 5751-5759.
5. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK (2003) Humoral, mucosal, and cellular immune responses to oral Noralk virus-like particles in volunteers. Clin Immunol 108: 241-247.
6. Warfield K, Bosio C, Welcher B, Deal E, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S (2003) Ebola virus-like particles protect form lethal Ebola virus infection. Proc Natl Acad Sci USA 100: 15889-15894.
7. Saini M, Gratis S (2003) A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J Virol 77: 3487-3494.
8. Sadeyen J, Toume S, Shkreli M, Sizaret P, Coursaget P (2003) Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology 309: 32-40.
9. Kang S, Yao Q, Guo LCR (2009) Mucosal immunization with virus-like particles of Simian Immunodeficiency Virus conjugated with Cholera Toxin Subunit B. J Virol 77(18): 9823-9830.
10. Alvarez-Lajonchere L, Gonzalez M, varez-Obregon JC, Guerra I, Vina A, costa-Rivero N, Musacchio A, Morales J, Duenas-Carrera S (2006) Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice. Biotechnol Appl Biochem 44: 9-17.
11. Storni T, Ruedl C, Schwarz K, Schwendener R, Renner W, Bachmann MF (2004) Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172: 1777-1785.
12. Lazo L, Hermida L, Zulueta A, Sanchez J, Lopez C, Silva R, Guillen G, Guzman MG (2007) A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine 25: 1064-1070.
13. Lopez C, Gil L, Lazo L, Menendez I, Marcos E, Sanchez J, Valdes I, Falcon V, de la Rosa MC, Marquez G, Guillen G, Hermida L (2009) In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Arch Virol 154: 695-698.
14. + cells against viral encephalitis in mice. Int Immunol 21(10): 1175-1183.
15. Zulueta A, Hermida L, Lazo L, Valdes I, Rodriguez R, Lopez C, Silva R, Rosario D, Martin J, Guzman MG, Guillen G (2003) The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun 308: 619-626.
16. Hermida L, Rodriguez R, Lazo L, Silva R, Zulueta A, Chinea G, Lopez C, Guzman MG, Guillen G (2004) A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 115: 41-49.
17. Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, Lopez C, Martinez R, Castro J, Santana E, Hermida L, Guillen G, Guzman MG (2008) Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 80: 194-199.
18. Gonzalez S, Alvarez A, Caballero E, Vina L, Guillen G, Silva R (2000) P64k meningococcal protein as immunological carrier for weak immunogens. Scand J Immunol 52: 113-116.
19. Perez A, Dickinson F, Cinza Z, Ruiz A, Serrano T, Sosa J, Gonzalez S, Gutierrez Y, Nazabal C, Gutierrez O, Guzman D, Diaz M, Delgado M, Caballero E, Sardinas G, Alvarez A, Martin A, Guillen G, Silva R (2001) Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol Appl Biochem 34: 121-125.
20. Zulueta A, Martin J, Hermida L, Alvarez M, Valdes I, Prado I, Chinea G, Rosario D, Guillen G, Guzman MG (2006) Amino acid changes in the recombinant Dengue 3 envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 121: 65-73.
21. Roehrig JT (2003) Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141-175.
22. Valdes I, Hermida L, Martin J, Menendez T, Gil L, Lazo L, Castro J, Niebla O, Lopez C, Bernardo L, Sanchez J, Romero Y, Martinez R, Guzman MG, Guillen G (2009) Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 27: 995-1001.
23. Lazo L, Zulueta A, Hermida L, Blanco A, Sanchez J, Valdes I, Gil L, Lopez C, Romero Y, Guzman MG, Guillen G (2009) Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 52: 265-271.
24. Kawano H, Rostapshov V, Rosen L, Lai CJ (1993) Genetic determinants of dengue type 4 virus neurovirulence for mice. J Virol 67: 6567-6575.
25. Clarke DH, Casals J (1958) Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7: 561-573.
26. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N (1985) Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22: 250-254.
27. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717-725.
28. Chen Y, Maguire T, Marks RM (1996) Demonstration of binding of dengue virus envelope protein to target cells. J Virol 70: 8765-8772.
29. Mune M, Rodriguez R, Ramirez R, Soto Y, Sierra B, Rodriguez RR, Marquez G, Garcia J, Guillen G, Guzman MG (2003) Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice. Arch Virol 148: 2267-2273.
30. Simmons M, Murphy GS, Hayes CG (2001) Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65: 159-161.
31. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W (2003) Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69: 48-60.
32. Vaughn DW (2000) Invited commentary: dengue lessons from Cuba. Am J Epidemiol 152: 800-803.
33. Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W (2008) Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg 79: 115-122.
34. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855-1862.
35. + cytotoxic T-lymphocyte clones. J Virol 70: 141-147.
36. Gagnon SJ, Ennis FA, Rothman AL (1999) Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol 73: 3623-3629.
37. + T cells to heterologous serotypes. J Immunol 175: 2676-2683.
38. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, Khemnu N, Tangthawornchaikul N, Chotiyarnwong P, Sae-Jang K, Koch M, Jones Y, McMichael A, Xu X, Malasit P, Screaton G (2006) T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol 176: 3821-3829.
39. van der Most RG, Murali-Krishna K, Ahmed R (2003) Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis. Int Immunol 15: 119-125.
40. van der Most RG, Murali-Krishna K, Ahmed R, Strauss JH (2000) Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 74: 8094-8101.
41. Iglesias E, Thompson R, Carrazana Y, Lobaina Y, Garcia D, Sanchez J, Garcia J, Cruz O, Brown E, Martin A, Muzio VL, Aguilar JC (2006) Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1. Immunol Cell Biol 84: 174-183.
42. Aguilar JC, Lobaina Y, Muzio V, Garcia D, Penton E, Iglesias E, Pichardo D, Urquiza D, Rodriguez D, Silva D, Petrovsky N, Guillen G (2004) Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 82: 539-546.
43. Chaung HC (2006) CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int Immunopharmacol 6: 1586-1596.
44. Riedl P, Stober D, Oehninger C, Melber K, Reimann J, Schirmbeck R (2002) Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol 168: 4951-4959.
45. Donnelly J, Berry K, Ulmer JB (2003) Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 33: 457-467.
46. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM (2001) Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167: 3555-3558.
47. Lobigs M, Mullbacher A, Lee E (2004) Evidence that a mechanism for efficient flavivirus budding upregulates MHC class I. Immunol Cell Biol 82: 184-188.
48. Gil L, Lopez C, Blanco A, Lazo L, Martin J, Valdes I, Romero Y, Figueroa Y, Guillen G, Hermida L (2009) The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 22: 23-30.